Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CDC42BPA_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CDC42BPA_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CDC42BPA_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CDC42BPA_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/CDC42BPA_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CDC42BPA_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CDC42BPA_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CDC42BPA_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CDC42BPA_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00315328 | Cervix | CC | actin cytoskeleton reorganization | 31/2311 | 107/18723 | 3.34e-06 | 8.99e-05 | 31 |
GO:00310329 | Cervix | CC | actomyosin structure organization | 43/2311 | 196/18723 | 1.11e-04 | 1.40e-03 | 43 |
GO:00181076 | Cervix | CC | peptidyl-threonine phosphorylation | 25/2311 | 116/18723 | 3.59e-03 | 2.30e-02 | 25 |
GO:00182106 | Cervix | CC | peptidyl-threonine modification | 26/2311 | 125/18723 | 4.98e-03 | 2.97e-02 | 26 |
GO:0031532 | Colorectum | AD | actin cytoskeleton reorganization | 41/3918 | 107/18723 | 2.81e-05 | 5.28e-04 | 41 |
GO:0031032 | Colorectum | AD | actomyosin structure organization | 65/3918 | 196/18723 | 4.17e-05 | 7.37e-04 | 65 |
GO:0018210 | Colorectum | AD | peptidyl-threonine modification | 40/3918 | 125/18723 | 2.44e-03 | 1.88e-02 | 40 |
GO:0018107 | Colorectum | AD | peptidyl-threonine phosphorylation | 37/3918 | 116/18723 | 3.68e-03 | 2.61e-02 | 37 |
GO:00315322 | Colorectum | MSS | actin cytoskeleton reorganization | 41/3467 | 107/18723 | 1.21e-06 | 4.06e-05 | 41 |
GO:00310322 | Colorectum | MSS | actomyosin structure organization | 53/3467 | 196/18723 | 2.04e-03 | 1.75e-02 | 53 |
GO:00181071 | Colorectum | MSS | peptidyl-threonine phosphorylation | 34/3467 | 116/18723 | 3.08e-03 | 2.34e-02 | 34 |
GO:00182101 | Colorectum | MSS | peptidyl-threonine modification | 36/3467 | 125/18723 | 3.28e-03 | 2.49e-02 | 36 |
GO:00315323 | Colorectum | FAP | actin cytoskeleton reorganization | 34/2622 | 107/18723 | 1.99e-06 | 8.03e-05 | 34 |
GO:00310323 | Colorectum | FAP | actomyosin structure organization | 51/2622 | 196/18723 | 5.89e-06 | 1.88e-04 | 51 |
GO:00182102 | Colorectum | FAP | peptidyl-threonine modification | 31/2622 | 125/18723 | 8.93e-04 | 9.08e-03 | 31 |
GO:00181072 | Colorectum | FAP | peptidyl-threonine phosphorylation | 29/2622 | 116/18723 | 1.12e-03 | 1.08e-02 | 29 |
GO:00315324 | Colorectum | CRC | actin cytoskeleton reorganization | 31/2078 | 107/18723 | 3.36e-07 | 2.83e-05 | 31 |
GO:00310324 | Colorectum | CRC | actomyosin structure organization | 45/2078 | 196/18723 | 1.49e-06 | 8.14e-05 | 45 |
GO:00181073 | Colorectum | CRC | peptidyl-threonine phosphorylation | 27/2078 | 116/18723 | 1.38e-04 | 2.58e-03 | 27 |
GO:00182103 | Colorectum | CRC | peptidyl-threonine modification | 28/2078 | 125/18723 | 2.10e-04 | 3.55e-03 | 28 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CDC42BPA | SNV | Missense_Mutation | | c.879N>C | p.Lys293Asn | p.K293N | Q5VT25 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
CDC42BPA | SNV | Missense_Mutation | rs779954841 | c.4831N>T | p.Pro1611Ser | p.P1611S | Q5VT25 | protein_coding | tolerated(0.1) | probably_damaging(0.998) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CDC42BPA | SNV | Missense_Mutation | novel | c.3781N>G | p.Ile1261Val | p.I1261V | Q5VT25 | protein_coding | tolerated(0.4) | benign(0.06) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CDC42BPA | SNV | Missense_Mutation | | c.4345N>A | p.Leu1449Ile | p.L1449I | Q5VT25 | protein_coding | deleterious(0.03) | benign(0.365) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CDC42BPA | SNV | Missense_Mutation | novel | c.526N>T | p.Asp176Tyr | p.D176Y | Q5VT25 | protein_coding | deleterious(0) | probably_damaging(0.946) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CDC42BPA | SNV | Missense_Mutation | novel | c.526G>A | p.Asp176Asn | p.D176N | Q5VT25 | protein_coding | deleterious(0) | possibly_damaging(0.551) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
CDC42BPA | SNV | Missense_Mutation | novel | c.4911N>A | p.Phe1637Leu | p.F1637L | Q5VT25 | protein_coding | tolerated(0.73) | benign(0) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
CDC42BPA | SNV | Missense_Mutation | | c.3761N>C | p.Lys1254Thr | p.K1254T | Q5VT25 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
CDC42BPA | SNV | Missense_Mutation | | c.3105N>A | p.Phe1035Leu | p.F1035L | Q5VT25 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
CDC42BPA | SNV | Missense_Mutation | | c.1483N>A | p.Glu495Lys | p.E495K | Q5VT25 | protein_coding | deleterious(0.02) | probably_damaging(0.923) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8476 | CDC42BPA | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | TAE-684 | TAE-684 | |
8476 | CDC42BPA | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | PF-562271 | PF-00562271 | |
8476 | CDC42BPA | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | GSK-269962A | GSK-269962A | |
8476 | CDC42BPA | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | CENISERTIB | CENISERTIB | |
8476 | CDC42BPA | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | LAUROGUADINE | LAUROGUADINE | |
8476 | CDC42BPA | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | ALSTERPAULLONE | ALSTERPAULLONE | |
8476 | CDC42BPA | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | inhibitor | 249565832 | | |
8476 | CDC42BPA | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | DASATINIB | DASATINIB | |
8476 | CDC42BPA | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | PHA-767491 | CHEMBL225519 | |
8476 | CDC42BPA | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | KENPAULLONE | KENPAULLONE | |